semaglutide vision loss Injectable weight drugs linked to rare loss Vision loss possibly linked to

GLP-1 Receptor Agonists and Related Mental Health Issues

Kaufman said he didnt want to sound hyperbolic about the new drugs, but then sounded pretty hyperbolic when he described his short, but so far positive, experience with them in these diseases as eye-opening and incredible

Three 24-week, placebo-controlled add-on combination therapy studies, one with metformin, one with pioglitazone, and one with glimepiride with or without metformin, were also conducted

The efficacy and safety of tirzepatide, with a special focus on cardiovascular safety, were investigated in the 52-week SURPASS-4 trial testing tirzepatide versus insulin glargine in adults with T2D and a high cardiovascular risk under inadequate glycemic control at baseline on one to three oral glucose-lowering medications (metformin, sulfonylurea, SGLT-2 inhibitor) (74)

Interested in Injectable or Oral Compounds